Hylenex recombinant is indicated for use as an adjuvant agent to increase the absorption and dispersion of other injected drugs, for hypodermoclysis, and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents. Hylenex recombinant is contraindicated in patients with hypersensitivity to hyaluronidase enzyme or any other ingredients in its formulation. The contraindications and warnings regarding the use of Hylenex should be recognized and adhered to before prescription or administration.

It is recommended that appropriate references be consulted concerning physical or chemical incompatibilities before adding Hylenex recombinant to a solution containing another drug.

Insert needle with aseptic safety measures. With tip lying free and movable between skin and muscle, start clysis; fluid should start in readily without pain or lump. Then inject Hylenex recombinant into rubber tube close to the needle. An alternate method is to inject Hylenex recombinant under skin before clysis. 150 U can facilitate absorption of 1,000 mL or more of solution. As with all parenteral fluid therapy, observe effect very much, with the same precautions for restoring fluid and electrolyte balance as in intravenous injections.  Hylenex recombinant may be added to small volumes of solution such as small clysis for infants or solutions of drugs for subcutaneous injection. For infants and children less than 3 years the volume of a single clysis should be limited to 200 mL; and in premature infants or during the neonatal period, the daily dosage should not exceed 25 mL/kg of body weight; the rate of administration should not be greater than 2 mL per minute. For older people, the rate and volume of administration should not exceed those employed for intravenous infusion.